In the US, about 160,000 bariatric operations are done in each year. Development of safer laparoscopic approaches has made this surgery more popular.
(See also Obesity.)
To qualify for bariatric surgery, patients should
Bariatric surgery should also be considered for patients with a BMI of 30 to 34.9 with type 2 diabetes who have inadequate glycemic control despite optimal lifestyle and medical therapy (1).
1. Mechanick JI, Apovian C, Brethauer S, et al: Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures – 2019 update: cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, The Obesity Society, American Society for Metabolic & Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists. . Article in Press, 2019. doi:10.4158/GL-2019-0406.
The most common procedures done in the US include
Most procedures are done laparoscopically, resulting in less pain and a shorter healing time than open surgery. Traditionally, bariatric surgery has been classified as restrictive and/or malabsorptive, referring to the presumptive mechanism of weight loss. However, other factors appear to contribute to weight loss; for example, RYGB (traditionally classified as malabsorptive) and sleeve gastrectomy (traditionally classified as restrictive) both result in metabolic or hormonal changes that favor satiety and weight loss and in other hormonal changes (eg, an increase in insulin release [incretin effect]) that appear to contribute to the rapid remission of diabetes.
After RYGB (particularly) or sleeve gastrectomy, levels of gastrointestinal hormones, such as glucagon-like peptide-1 (GLP-1) and peptide YY (PYY), are increased, possibly contributing to satiety, weight loss, and remission of diabetes. Increased insulin sensitivity is evident immediately postoperatively, before significant weight loss occurs, suggesting that neurohormonal factors are prominent in remission of diabetes. A change in gut microbiome may also contribute to changes in weight after RYGB.
RYGB is usually done laparoscopically. A small part of the proximal stomach is detached from the rest, creating a stomach pouch of < 30 mL. Also, food bypasses part of the stomach and small intestine, where it is normally absorbed, reducing the amount of food and calories absorbed. The pouch is connected to the proximal jejunum; the opening between them is narrow, limiting the rate of gastric emptying. The segment of small intestine connected to the bypassed stomach is attached to the distal small intestine. This arrangement allows bile acids and pancreatic enzymes to mix with gastrointestinal contents, limiting malabsorption and nutritional deficiencies.
RYGB is particularly effective in treating diabetes; remission rates are up to 62% after 6 years.
For many patients who have had RYGB, eating high-fat and high-sugar foods can cause dumping syndrome; symptoms can include light-headedness, diaphoresis, nausea, abdominal pain, and diarrhea. Dumping syndrome may inhibit the consumption of such foods by adverse conditioning.
In the past, sleeve gastrectomy was done only when patients are considered too high risk for procedures such as RYGB and biliopancreatic diversion (eg, patients with a BMI > 60), typically before one of these procedures or another similar procedure is done. However, because sleeve gastrectomy causes substantial and sustained weight loss, it is being used in the US as definitive treatment for severe obesity. Part of the stomach is removed, creating a tubular stomach passage. The procedure does not involve anatomic changes to the small intestine.
Mean excess weight loss tends to be higher than with that with adjustable gastric banding. Although sleeve gastrectomy is traditionally classified as a restrictive procedure, weight loss is probably also related to neurohormonal changes.
The most serious complication is gastric leak at the suture line; it occurs in 1 to 3% of patients.
Use of adjustable gastric banding has dramatically decreased in the US. A band is placed around the upper part of the stomach to divide the stomach into a small upper pouch and a larger lower pouch. Typically, the band is adjusted 4 to 6 times by injecting saline into the band via a port that is placed subcutaneously. When saline is injected, the band expands, restricting the upper pouch of the stomach. As a result, the pouch can hold much less food, patients eat more slowly, and satiety occurs earlier. This procedure is usually done laparoscopically. Saline can be removed from the band if a complication occurs or if the band is overly restrictive.
Weight loss with the band varies and is related to the frequency of follow-up; more frequent follow-ups result in greater weight loss. Although postoperative morbidity and mortality are less than those with RYGB, long-term complications, including repeat operations, are more likely, possibly occurring in up to 15% of patients.
This procedure accounts for < 5% of bariatric procedures done in the US.
Part of the stomach is removed, causing restriction. The remaining part empties into the duodenum. The duodenum is cut and attached to the ileum, bypassing much of the small intestine, including the sphincter of Oddi (where bile acids and pancreatic enzymes enter); as a result, food absorption decreases. This procedure is technically demanding but can sometimes be done laparoscopically.
Malabsorption and nutritional deficiencies often develop.
Vertical banded gastroplasty is no longer commonly done because complication rates are high and the resulting weight loss is insufficient. For this procedure, a stapler is used to divide the stomach into a small upper pouch and a larger lower pouch. A nonexpandable plastic band is placed around the opening where the upper pouch empties into the lower pouch.
Preoperative evaluation consists of
Diagnosis and correction of comorbid conditions as much as possible
Assessment of readiness and ability to engage in lifestyle modification
Exclusion of contraindications to surgery
Review of the postoperative diet and assessment of the patient's ability to make necessary lifestyle changes by a dietitian
Identification of any uncontrolled psychiatric disorder and any dependencies that would preclude surgery and identification and discussion of potential obstacles to adherence to lifestyle changes postoperatively by a psychologist or other qualified mental health care practitioner
Extensive preoperative evaluation is not routinely necessary, but preoperative testing may be necessary based on clinical findings, and measures to control certain conditions (eg, hypertension) or reduce risk may be taken.
Pulmonary: Patients at risk of obstructive sleep apnea based on clinical suspicion should be screened with polysomnography, and if obstructive sleep apnea is present, patients should be treated with continuous positive airway pressure (CPAP). This diagnosis indicates risk of cardiovascular morbidity and premature death. Smoking increases risk of pulmonary complications, ulcers, and gastrointestinal bleeding postoperatively. Smoking should be stopped at least 6 weeks but preferably 1 year before surgery to minimize perioperative complications and indefinitely thereafter.
Cardiac: Preoperative ECG and other noninvasive cardiac testing is considered if individual risk warrants, even for asymptomatic patients, to identify occult coronary artery disease. Even though obesity increases risk of pulmonary hypertension, echocardiography is not done routinely. Other cardiac testing is not done routinely; rather it is done based on the patient's risk factors for coronary artery disease, risk of surgery, and functional status. Blood pressure should be optimally controlled before surgery. During the perioperative period, risk of acute kidney injury is increased; thus, diuretics, angiotensin-converting enzyme (ACE) inhibitors, and angiotensin II receptor blockers (ARBs), if needed, should be used cautiously during this time.
Gastrointestinal (GI): Preoperative endoscopy or GI imaging studies should be done for patients with clinically significant GI symptoms. To reduce the risk of marginal ulcers, clinicians may test for and treat Helicobacter pylori infection, although evidence for the necessity of such treatment preoperatively is inconsistent.
Hepatic: Increased liver enzymes, especially alanine aminotransferase (ALT), are common among candidates for bariatric surgery and may indicate fatty liver disease. Clinically significant and persistently elevated liver enzymes should be evaluated, should not be assumed to result from fatty liver, and should prompt an investigation for other causes of abnormal liver enzyme levels. If prophylactic cholecystectomy is planned during bariatric surgery (to decrease risk of cholelithiasis), liver ultrasonography may be done.
Metabolic bone disease: Obese patients are at risk of vitamin D deficiency and metabolic bone disease, sometimes with secondary hyperparathyroidism. Patients should be screened and treated for these disorders before surgery, particularly because vitamin D deficiency is common preoperatively and poor absorption develops postoperatively.
Diabetes: Because poorly controlled diabetes increases the risk of adverse surgical outcomes, glycemic control should be optimized before surgery. A reasonable target range for HbA1c, corresponding to preoperative blood sugar control that may predict shorter hospital stays and improved bariatric procedure outcomes, is 6.5 to 7.0%.
Nutrition: Obese patients are at risk of nutritional deficiencies, which can be exacerbated postoperatively because food preferences and tolerance change, stomach acidity changes, and absorption from the small intestine is decreased. Routine measurement of vitamin D, vitamin B12, folate, and iron levels is recommended. For certain patients, measuring levels of other nutrients, such as thiamin (vitamin B1), may also be indicated.
Reproductive health: Women of reproductive age should be advised that their fertility may improve after surgery. These women should be counseled on contraceptive choice before and after bariatric procedures and should avoid pregnancy prior to surgery and postoperatively for 12 to 18 months. Patients undergoing malabsorptive procedures should have nutritional surveillance and laboratory testing for nutrient deficiencies every trimester.
Perioperative risks are lowest when bariatric surgery is done in an accredited center.
Gastric and/or anastomotic leaks (in 1 to 3%)
Pulmonary complications (eg, ventilator dependence, pneumonia, pulmonary embolism)
These complications can cause significant morbidity, prolong hospitalization, and increase costs. Tachycardia may be the only early sign of anastomotic leak.
Later problems may include prolonged nausea and vomiting secondary to small-bowel obstruction and anastomotic stenosis.
Nutritional deficiencies (eg, protein-energy undernutrition, vitamin B12 deficiency, iron deficiency) may result from inadequate intake, inadequate supplementation, or malabsorption. Malodorous flatulence, diarrhea, or both may develop, particularly after malabsorptive procedures. Calcium and vitamin D absorption may be impaired, causing deficiencies and sometimes hypocalcemia and secondary hyperparathyroidism. With prolonged vomiting, thiamin deficiency may occur.
Incidence of psychologic disorders such as depression is increased in patients having bariatric surgery. A 2016 meta-analysis confirmed this increase in preoperative depression and reported a postoperative decrease in the prevalence and severity of depression (1). One large study suggested that the risk of suicide in patients who had bariatric surgery was increased compared with that in controls (2.7 versus 1.2 per 10,000 person-year; hazard ratio 1.71 [0.69 to 4.25]; P value = 0.25 ). Incidence of alcohol use disorder also appears to be increased after bariatric surgery (3).
Eating habits may be disordered. Adjusting to new eating habits can be difficult.
1. Dawes AJ, Maggard-Gibbons M, Maher AR, et al: Mental health conditions among patients seeking and undergoing bariatric surgery: A meta-analysis. JAMA 315 (2):150–163, 2016. doi: 10.1001/jama.2015.18118.
2. Adams TD, Gress RE, Smith SC, et al: Long-term mortality after gastric bypass surgery. N Engl J Med 357:753–761, 2007.
3. Heinberg LJ, Ashton K, Coughlin J: Alcohol and bariatric surgery: review and suggested recommendations for assessment and management. Surg Obes Relat Dis 8 (3):357-363, 2012. doi: 10.1016/j.soard.2012.01.016.
In hospitals accredited by the American Society of Bariatric Surgery as centers of excellence (COE), overall 30-day mortality is 0.2 to 0.3%. However, some data indicate that lower rates of serious complications are predicted more accurately by the number of procedures done in the hospital and by the surgeon than by COE status.
Mortality is higher with Roux-en-Y gastric bypass (RYGB) than laparoscopic adjustable gastric banding and higher with open procedures (2.1%) than laparoscopic procedures (0.2%). Factors that predict higher risk of mortality include a history of deep venous thrombosis or pulmonary embolism, obstructive sleep apnea, and poor functional status. Other factors such as severe obesity (BMI > 50), older age, and male sex have also been associated with higher risk, but the evidence is inconsistent.
Average excess weight loss depends on the procedure.
For laparoscopic adjustable gastric banding, weight loss is
Percentage of weight loss is related to the frequency of follow-ups and number of band adjustments. Patients with a lower BMI tend to lose more excess weight than those with a higher BMI.
For sleeve gastrectomy, weight loss is
Longer-term data are not available.
For Roux-en-Y gastric bypass, weight loss is
Weight loss after RYGB is maintained for up to 10 years.
Comorbid conditions that tend to abate or resolve after bariatric surgery include cardiovascular risk factors (eg, dyslipidemia, hypertension, diabetes), cardiovascular disorders, diabetes, obstructive sleep apnea, osteoarthritis, and depression. Diabetes is particularly likely to remit (eg, with RYGB, up to 62% of patients at 6 years). All-cause mortality decreases by 25%, primarily because cardiovascular and cancer mortality is reduced.
Regular, long-term follow-up helps ensure adequate weight loss and prevent complications. After Roux-en-Y gastric bypass or sleeve gastrectomy, patients should be monitored every 4 to 12 weeks during the period of rapid weight loss (usually about the first 6 months after surgery), then every 6 to 12 months thereafter. With laparoscopic adjustable gastric banding, results appear to be optimal when patients are monitored and the band is adjusted at least 6 times during the first year after surgery.
Weight and blood pressure are checked, and eating habits are reviewed. Blood tests (usually complete blood count, electrolytes, glucose, blood urea nitrogen, creatinine, albumin, and protein and liver tests) are done at regular intervals. Glycosylated Hb (HbA1c) and fasting lipid levels should be monitored if they were abnormal before surgery. Depending on the type of procedure, vitamin and mineral levels, including calcium, vitamin D, vitamin B12, folate, iron, and thiamin (vitamin B1), may need to be monitored. Because secondary hyperparathyroidism is a risk, parathyroid hormone levels should also be monitored. Bone density should be measured after sleeve gastrectomy or Roux-en-Y gastric bypass.
Clinicians should check for any changes in response to antihypertensives, insulin, oral hypoglycemics, or lipid-lowering drugs during the period of rapid weight loss after surgery.
Patients should be regularly evaluated for gout, cholelithiasis, and nephrolithiasis, all of which can develop after bariatric surgery. Prophylactic ursodiol reduces risk of cholelithiasis and should be offered after bariatric surgery. Patients should also be regularly screened for depression and alcohol use, particularly if alcohol use was heavy preoperatively.
To minimize risk of hypoglycemia (due to increased insulin sensitivity after bariatric surgery) in patients with diabetes, clinicians should adjust the dose of insulin and decrease the dose of oral hypoglycemics (particularly sulfonylureas) or stop them after Roux-en-Y gastric bypass or sleeve gastrectomy.
Consider weight loss surgery if patients are motivated, have not succeeded using nonsurgical treatments, and have a BMI of > 40 kg/m2 or a BMI of > 35 kg/m2 plus a serious complication (eg, diabetes, hypertension, obstructive sleep apnea, high-risk lipid profile) or a BMI of 30 to 34.9 with type 2 diabetes and inadequate glycemic control despite optimal lifestyle and medical therapy.
Weight loss surgery is contraindicated if patients have an uncontrolled psychiatric disorder (eg, major depression), drug or alcohol abuse, cancer that is not in remission, or another life-threatening disorder or if they cannot comply with nutritional requirements (including life-long vitamin replacement when indicated).
The most common procedure is Roux-en-Y gastric bypass, followed by sleeve gastrectomy; use of adjustable gastric banding has decreased dramatically in the US.
Monitor patients regularly after surgery for maintenance of weight loss, resolution of weight-related comorbid disorders, and complications of surgery (eg, nutritional deficiencies, metabolic bone disease, gout, cholelithiasis, nephrolithiasis, depression, alcohol abuse).
Drugs Mentioned In This Article
|Drug Name||Select Trade|